Calendar

Events that a source expects, grouped by the month, quarter or half-year the source names, with who expected each and when they said so.

Upcoming as of , the date this release was built (the newest input commit date), not today's date. An expected date is a statement by the source, not a result, and it can move. Dated events are on the timeline.

8,817 of these dates come from registry records: the start, primary completion or completion that a registry expects of a trial. A program assembled them, and a registry often leaves a date unchanged after it has passed. The calendar file lists the dates of written pages only.

Add to your calendar (calendar.ics)

The calendar file has one all-day event for each upcoming item. Where a source gives only a month, a quarter, a half-year or a year, the event sits on the first day of that period and its title says "expected sometime in" the period.

Upcoming

All 4,307 are listed on earlier pages.

Overdue

The expected date has passed and no published record says the event happened. This does not mean it failed or was delayed: the atlas may not have checked the source since. Oldest first.

  1. Study completion Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06773663

  2. Primary completion A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07026968

  3. Primary completion Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07290751

  4. Primary completion A Study of VCT220 in Participants With Hypertension and Obesity or Overweight Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07360275

  5. Study completion A Study on the Effect of Electronic Moxibustion Based on Ziwu Liuzhu in Treating Constipation in Stroke Patients Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07372326

  6. Study completion Blended Resources for Integrated Diabetes Guidance and Empowerment Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07373379

  7. Primary completion High-Flow Nasal Cannula Versus Non-Invasive Ventilation for Acute Respiratory Failure in Pulmonary Embolism. Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07381712

  8. Primary completion Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07423975

  9. Study start Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07751965

  10. Study start Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07806279

  11. Study start A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus Registry record

    Expected 2026-10-30; that period ended on 2026-10-30.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07923357

  12. Primary completion CardioFocus HeartLight Post-Approval Study Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT03168659

  13. Primary completion Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT03183895

  14. Study completion Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT03621501

  15. Primary completion Advancing Postmenopausal Preventive Therapy Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT04103476

  16. Primary completion Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT04217421

  17. Primary completion Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT04763200

  18. Study completion Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05119179

  19. Primary completion Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05119179

  20. Study completion Precise Procedural and PCI Plan (P4) Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05253677

  21. Study completion To Assess the Safety and Efficacy of the Atrial Shunt Implant System in the Treatment of Patients With Chronic Left Heart Failure Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05486000

  22. Primary completion To Assess the Safety and Efficacy of the Atrial Shunt Implant System in the Treatment of Patients With Chronic Left Heart Failure Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05486000

  23. Primary completion Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05598333

  24. Study completion A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06037252

  25. Study completion Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06365697

  26. Study completion Study of JK07 in Patients With Chronic Heart Failure Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06369298

  27. Primary completion Study of JK07 in Patients With Chronic Heart Failure Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06369298

  28. Study completion Tirofiban for Successful Endovascular Stroke Thrombectomy Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06373042

  29. Study completion EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06386874

  30. Study completion Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06479343

  31. Study completion Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06616961

  32. Primary completion BIO|MASTER.CSP Study Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06620237

  33. Study completion Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06645249

  34. Study completion Standardized Goal-Directed vs. Self-Directed Valsalva Maneuver for the Assessment of Patent Foramen Ovale Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06670781

  35. Primary completion Standardized Goal-Directed vs. Self-Directed Valsalva Maneuver for the Assessment of Patent Foramen Ovale Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06670781

  36. Primary completion Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06866236

  37. Primary completion Novel Chinese Medicine Formula for Diabetes Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06978023

  38. Primary completion NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07018596

  39. Study start Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07083765

  40. Primary completion Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07090161

  41. Study completion Post-stroke Nurse-led Rehabilitation to Improve Functional Activity and Community Participation in Bangladesh Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07384650

  42. Study start Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07389941

  43. Primary completion Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07396337

  44. Study completion Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07508254

  45. Study start Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07511543

  46. Study completion HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07546929

  47. Primary completion HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07546929

  48. Study start Multi-Site STARgraft (10401) Trial Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07557862

  49. Study start Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07575828

  50. Study start Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07684469

  51. Study start Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07735338

  52. Study start ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms. Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07737964

  53. Study start Oral Versus Intravenous Tranexamic Acid in Off-Pump Coronary Artery Bypass Surgery Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07740330

  54. Study start A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07742098

  55. Study start Assessment of Dietary Balance in Home-Dwelling Patients With Stage 4 and 5 Chronic Kidney Disease Using URIKI (IKI), a Connected Urine Test Strip and In Vitro Diagnostic Medical Device Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07746037

  56. Study start Implementing Improved Blood Pressure Measurement in General Practice: A Multisite Implementation Trial Using Automated Office Blood Pressure (AOBP) Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07822022

  57. Study start REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07834372

  58. Study start Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07835581

  59. Study start A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07835984

  60. Study start AI-Based Personalized Self-Management for Patients With Heart Failure Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07841665

  61. Study start A Study of HRS-4729 Injection in Participants With Type 2 Diabetes Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07843862

  62. Study start A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07848880

  63. Study start Vortosiran for VTE Prevention Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07850453

  64. Study start Upper Extremity Orthoses Combined With Occupational Therapy in Subacute Stroke Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07864090

  65. Study start Pulsed Field Ablation for Paroxysmal Atrial Fibrillation: Clinical Efficacy and Left Atrial Function Protection Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07865221

  66. Study start Tolerability and Safety of Nano-Tocotrienols Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07888426

  67. Study start Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease Registry record

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07891650

  68. Study start Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension Registry record

    Expected 2026-10-31; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07910058

  69. Primary completion ORION-4 (inclisiran outcome trial)

    Expected 2026-10; that period ended on 2026-10-31.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

  70. Study completion Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT04676880

  71. Primary completion ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT05686317

  72. Primary completion Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06705010

  73. Primary completion SIRAKI 02 Posthoc Analysis. Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06781294

  74. Study start Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06882772

  75. Study start Metabolic Surgery for Atrial Fibrillation Elimination Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07027969

  76. Primary completion The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07103655

  77. Study completion SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07105917

  78. Study completion Perioperative Argon Inhalation to Improve Neurocognitive Recovery After Carotid Surgery Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07200180

  79. Study start Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07238452

  80. Study start Silicon-based Photon Counting Computed Tomography for Advanced Cardiac Imaging Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07411196

  81. Study start Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07763405

  82. Study start Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07852637

  83. Study start A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07872436

  84. Study start Haptic-Assisted Virtual Reality Upper-Limb Rehabilitation After Intracerebral Haemorrhage Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07882810

  85. Study start A Novel Wire-Reinforced Fenestration of a Hybrid Frozen Elephant Trunk Device for Supra-Aortic Branch Vessel Stenting During Aortic Arch Replacement Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07885865

  86. Study start Superficial Parasternal Block Combined With Rectus Sheath Block for Open Cardiac Surgery Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07890857

  87. Study start Metformin in Acute Ischemic Stroke Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07899307

  88. Study start Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07901595

  89. Study start Implementation Study on Hospital-to-home Advanced Rehabilitation Technologies (ART) Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07904624

  90. Study start Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07917078

  91. Study start Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT) Registry record

    Expected 2026-11-01; that period ended on 2026-11-01.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07920055

  92. Study start Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch Registry record

    Expected 2026-11-02; that period ended on 2026-11-02.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07540416

  93. Study start Furosemide vs Placebo in Severe Preeclampsia Postpartum Registry record

    Expected 2026-11-02; that period ended on 2026-11-02.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07648251

  94. Study start Continuous Glucose Monitoring and Dietary Self-Management in Adults in Namwon Registry record

    Expected 2026-11-02; that period ended on 2026-11-02.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07890740

  95. Study start Study of the Safety and Efficacy of Prenofitol Tablets Registry record

    Expected 2026-11-02; that period ended on 2026-11-02.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07908433

  96. Primary completion Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia Registry record

    Expected 2026-11-04; that period ended on 2026-11-04.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06772168

  97. Study start A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin Registry record

    Expected 2026-11-06; that period ended on 2026-11-06.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07796477

  98. Primary completion Grid eXplore Mapping Study Registry record

    Expected 2026-11-07; that period ended on 2026-11-07.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07421076

  99. Study start Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty Registry record

    Expected 2026-11-09; that period ended on 2026-11-09.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT07770633

  100. Study completion A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) Registry record

    Expected 2026-11-10; that period ended on 2026-11-10.

    Date listed by U.S. National Library of Medicine (ClinicalTrials.gov), retrieved on .

    Source: ClinicalTrials.gov record NCT06660173